Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 14 of 6351
-
CRISPR stem cell therapy shows promise for kids with sickle cell
Disease control OngoingThis is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a brain implant let paralyzed people control computers with their minds?
Disease control OngoingThe Synchron motor neuroprosthesis (MNP) is intended to be used in subjects with severe motor impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning motor cortex. The purpose of this research is to evaluate safety and feasibility. The MNP is a…
Sponsor: Synchron Medical, Inc. • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
Can immunotherapy help patients keep their voice box?
Cure CompletedThis a prospective, single-arm, multi-institutional, open label, phase 2 trial evaluating the effects of induction chemo-immunotherapy, followed by radioimmunotherapy, followed by consolidation immunotherapy in patients with locally advanced squamous cell carcinoma of the larynx …
Phase 2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Cure
Last updated Aug 29, 2026 00:00 UTC
-
Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
Disease control OngoingA Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Phase 3 • Sponsor: Curium US LLC • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a single eye injection restore sight in genetic blindness?
Cure OngoingThis is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects…
Phase 1/2 • Sponsor: Ocugen • Aim: Cure
Last updated Aug 02, 2026 00:00 UTC
-
Can a single gene shot free hemophilia b patients from regular infusions?
Cure Stopped earlyStudy of FLT180a gene therapy in adults with Hemophilia B. Up to 9 patients will be enrolled to receive a single dose of FLT180a and be followed for 52 weeks. Results will confirm the dose for a future Phase 3 study.
Phase 1/2 • Sponsor: Spur Therapeutics • Aim: Cure
Last updated Aug 02, 2026 00:00 UTC
-
Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
Cure Recruiting nowThis phase I trial evaluates the best dose, possible benefits and/or side effects of fludarabine and cyclophosphamide with or without rituximab before CD19 chimeric antigen receptor T cells in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or h…
Phase 1 • Sponsor: University of California, Davis • Aim: Cure
Last updated Jul 19, 2026 00:00 UTC
-
Major RSV vaccine trial for seniors nears completion
Vaccine OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
Major RSV vaccine trial aims to protect seniors from severe lung infections
Vaccine CompletedThe study will enroll up to 27,200 participants in order to demonstrate the efficacy of the active Ad26.RSV.preF-based study vaccine in the prevention of Reverse Transcription Polymerase Chain Reaction (RT-PCR) confirmed Respiratory Syncytial Virus (RSV)-mediated Lower Respirator…
Phase 3 • Sponsor: Janssen Vaccines & Prevention B.V. • Aim: Vaccine
Last updated Jun 27, 2026 07:57 UTC
-
Twice-Yearly shot could revolutionize HIV prevention
Prevention OngoingThe goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection. The primary ob…
Phase 3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Jun 27, 2026 08:06 UTC
-
Immune-Boosting cocktail aims to free HIV patients from daily medication
Cure OngoingThe purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Cure
Last updated Aug 28, 2026 00:00 UTC
-
Can a shot stop ALS before it starts? new trial tests tofersen in gene carriers
Disease control OngoingThe primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen a…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for advanced breast cancer: targeted drug combo tested in major trial
Disease control OngoingThe study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a Two-Drug combo finally beat chronic hepatitis b?
Cure CompletedThis is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection
Phase 2 • Sponsor: Brii Biosciences Limited • Aim: Cure
Last updated Jul 25, 2026 00:00 UTC
-
Gene therapy breakthrough offers hope for rare brain disease
Disease control By invitation onlyCanavan Disease is a congenital white matter disorder caused by mutations to the gene encoding for aspartoacylase (ASPA). Expression of ASPA is restricted to oligodendrocytes, the sole white matter producing lineage in the brain. ASPA supports myelination in the capacity of its s…
Phase 1/2 • Sponsor: Myrtelle Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Could this cell therapy free type 1 diabetes patients from insulin?
Disease control Recruiting nowThis study will evaluate the safety, tolerability and efficacy of VX-880 infusion and VX-017 infusion in participants with type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
One-Time gene therapy aims to halt rare, fatal brain disease in children
Disease control OngoingPBGM01 is a gene therapy for GM1 gangliosidosis intended to deliver a functional copy of the GLB1 gene to the brain and peripheral tissues. This study will assess in a 2 part design the safety, tolerability and efficacy of PBGM01 in patients with early onset infantile (Type 1) an…
Phase 1/2 • Sponsor: Gemma Biotherapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take aim at Tough-to-Treat blood cancers
Disease control Recruiting nowThis is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.
Phase 1/2 • Sponsor: Curocell Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
Disease control OngoingThis Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
Phase 3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
CRISPR gene therapy: a Long-Term safety check for blood disease patients
Disease control By invitation onlyThis is a multi-site, open- label rollover study to evaluate the long-term safety and efficacy of CTX001 in pediatric and adult participants who received CTX001 in parent studies 111 (NCT03655678) 141 (NCT05356195) or 161 (NCT05477563) (transfusion-dependent β-thalassemia \[TDT\]…
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC